纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | Asgr1 |
Uniprot No | P07306 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 68-291aa |
氨基酸序列 | EELRGLRETFSNFTASTEAQVKGLSTQGGNVGRKMKSLESQLEKQQKDLSEDHSSLLLHVKQFVSDLRSLSCQMAALQGNGSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETELDKASQEPPLL |
预测分子量 | 29.7kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Asgr1重组蛋白的模拟参考文献示例(非真实文献,供参考):
1. **"Expression and Functional Characterization of Recombinant ASGR1 in Hepatocyte Targeting"**
- 作者:Zhang L. et al. (2020)
- 摘要:研究通过哺乳动物表达系统(HEK293)成功制备重组Asgr1蛋白,验证其与去唾液酸糖蛋白的特异性结合能力,并探讨其在肝细胞靶向药物递送中的应用潜力。
2. **"Structural Insights into ASGR1-Ligand Interactions Using Recombinant Protein Crystallography"**
- 作者:Smith J.R. et al. (2019)
- 摘要:利用重组Asgr1蛋白进行X射线晶体学分析,解析其配体结合域的三维结构,揭示关键氨基酸残基在糖识别中的作用,为肝靶向疗法设计提供依据。
3. **"ASGR1 Recombinant Protein-Based Nanoparticles for Liver-Specific Gene Delivery"**
- 作者:Wang Y. et al. (2021)
- 摘要:开发基于重组Asgr1蛋白的功能化纳米颗粒,证明其可高效靶向肝细胞并递送基因药物,在小鼠模型中显著降低非特异性毒性。
4. **"Purification and Functional Analysis of ASGR1 in Cholesterol Metabolism Regulation"**
- 作者:Kim S. et al. (2018)
- 摘要:通过大肠杆菌系统表达并纯化重组Asgr1.发现其参与调控肝脏胆固醇内吞途径,为代谢性疾病治疗提供新靶点。
(注:以上内容为模拟生成,实际文献需通过学术数据库检索验证。)
Asialoglycoprotein receptor 1 (ASGR1) is a transmembrane protein predominantly expressed on the surface of hepatocytes, playing a critical role in glycoprotein homeostasis. It belongs to the C-type lectin family and recognizes glycoproteins with terminal galactose or N-acetylgalactosamine residues, mediating their endocytosis and lysosomal degradation. Structurally, ASGR1 forms hetero- or homo-oligomers with ASGR2 through a conserved coiled-coil domain, functioning as a receptor complex in liver-specific clearance of desialylated proteins, apoptotic cells, and pathogens.
The recombinant ASGR1 protein, typically produced in mammalian expression systems like CHO or HEK293 cells, retains ligand-binding capacity and structural integrity. Its recombinant form enables studies on receptor-ligand interactions, cellular uptake mechanisms, and liver-targeted drug delivery systems. Researchers utilize ASGR1 recombinant proteins to investigate liver diseases such as hepatocellular carcinoma, viral hepatitis, and metabolic disorders, where receptor dysfunction or altered expression has been observed. Notably, ASGR1's liver-specific expression profile makes it a promising therapeutic target, with applications in developing ligand-conjugated nanoparticles, gene therapies, and diagnostic tools for hepatic conditions.
Recent studies highlight its potential in cholesterol metabolism regulation, with ASGR1 loss-of-function variants linked to reduced cardiovascular risk. This discovery has spurred interest in ASGR1-targeted therapies for atherosclerosis. The recombinant protein also serves as a critical tool for validating ASGR1 inhibitors and optimizing liver-directed therapeutic payloads, bridging basic research with clinical translation in hepatology and precision medicine.
×